Physician profile
Michael Monzel
NPI 1437133659
$7,603.17
in general payments reported to CMS, 2019-2025
30 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $643 · 2021: $1,395 · 2022: $2,026 · 2023: $1,217 · 2024: $593 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,961.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,114.58 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,163.46 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $772.78 | 2019-2024 | Entyvio, Gattex |
| Echosens North America, INC. | $578.37 | 2019 | |
| Gilead Sciences, INC. | $428.41 | 2019-2024 | Epclusa |
| Celgene Corporation | $299.53 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $286.48 | 2019-2024 | Stelara, Remicade, Simponi |
| Boston Scientific Corporation | $274.42 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $221.01 | 2020-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $176.36 | 2021-2023 | |
| Madrigal Pharmaceuticals | $146.26 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $139.25 | 2022-2024 | Linzess |
| Redhill Biopharma INC. | $132.70 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.36 | 2023 | Cyltezo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $87.21 | 2022-2023 | |
| Ucb, INC. | $76.62 | 2019-2020 | |
| Allergan, INC. | $76.03 | 2019-2020 | |
| Pfizer INC. | $61.78 | 2023-2024 | |
| Genzyme Corporation | $56.95 | 2022-2023 | |
| Braintree Laboratories, INC. | $45.53 | 2021-2023 | Sutab |
| Amgen INC. | $42.96 | 2022-2023 | Avsola, Amjevita |
| Shire North American Group INC | $31.97 | 2019 | |
| Shionogi INC | $29.87 | 2019 | |
| Vivus LLC | $29.53 | 2021-2023 | Qsymia |
| Ambu INC. | $28.75 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $25.47 | 2024-2025 | Voquezna |
| Cumberland Pharmaceuticals, INC. | $17.06 | 2022 | |
| Merck Sharp & Dohme LLC | $15.17 | 2020 | |
| Dova Pharmaceuticals | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Monzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.